secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARDELYX, INC. (ARDX)
CIK:        0001437402
Form:       8-K
Filed at:   2023-10-31T23:59:59+00:00
Accession:  0001628280-23-035596
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ardelyx reports Q3 net income $6.6M; IBSRELA sales $22.3M; raises FY guidance to $76-78M
--------------------------------------------------------------------------------

- Q3 net income $6.6M ($0.03/share) vs net loss $22.9M in Q3 2022; total revenue $56.4M vs $5.0M.
- IBSRELA U.S. net sales $22.3M (22% QoQ growth); FY 2023 guidance raised to $76-78M.
- XPHOZAH FDA approved Oct 17, 2023; commercial launch underway, product in channel early Nov.
- Cash, cash equivalents & short-term investments $165.1M at Sep 30; ~$218.1M as of Oct 30.
- Received $30M milestone from Kyowa Kirin for Japan approval; drew $22.5M from SLR loan amendment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1437402/000162828023035596/0001628280-23-035596-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1437402/000162828023035596/ardx-20231031.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-035596

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer